{"id":"dexamethasone-cytarabine-etoposide-pegylated-asparaginase","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Pancreatitis"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dexamethasone is a corticosteroid that promotes apoptosis in lymphoid cells. Cytarabine and etoposide are chemotherapy agents that inhibit DNA synthesis and topoisomerase II respectively, causing cell death. Pegylated-asparaginase depletes asparagine, an amino acid essential for leukemic cell protein synthesis, particularly affecting cells dependent on exogenous asparagine supply.","oneSentence":"This combination regimen uses a corticosteroid, cytotoxic chemotherapy agents, and an amino acid-depleting enzyme to induce apoptosis and inhibit protein synthesis in leukemic cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:55.095Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute lymphoblastic leukemia (ALL) in pediatric patients"},{"name":"Acute myeloid leukemia (AML) in pediatric patients"}]},"trialDetails":[{"nctId":"NCT05681260","phase":"PHASE3","title":"Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2023-02-06","conditions":"T-cell Lymphoblastic Lymphoma","enrollment":200},{"nctId":"NCT02845882","phase":"PHASE3","title":"LBL-2016 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2016-01","conditions":"Lymphoblastic Lymphoma","enrollment":150},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":475},{"nctId":"NCT00400946","phase":"PHASE3","title":"05-001: Treatment of Acute Lymphoblastic Leukemia in Children","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2005-04","conditions":"Drug/Agent Toxicity by Tissue/Organ, Leukemia","enrollment":800},{"nctId":"NCT03020030","phase":"PHASE3","title":"Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-03-03","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":560},{"nctId":"NCT02881086","phase":"PHASE3","title":"Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment","status":"COMPLETED","sponsor":"Goethe University","startDate":"2016-08","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":1023},{"nctId":"NCT02553460","phase":"PHASE1, PHASE2","title":"Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-01-29","conditions":"Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT03117751","phase":"PHASE2, PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma","enrollment":790},{"nctId":"NCT02101853","phase":"PHASE3","title":"Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-17","conditions":"Recurrent B Acute Lymphoblastic Leukemia","enrollment":669},{"nctId":"NCT02112916","phase":"PHASE3","title":"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-10-04","conditions":"Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma","enrollment":847},{"nctId":"NCT02003222","phase":"PHASE3","title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-05-19","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","enrollment":488},{"nctId":"NCT02883049","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-02-29","conditions":"B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia","enrollment":5949},{"nctId":"NCT07227584","phase":"PHASE2","title":"ALL Backbone in AYAs","status":"NOT_YET_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2026-04","conditions":"Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL)","enrollment":67},{"nctId":"NCT04501614","phase":"PHASE1, PHASE2","title":"A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"Takeda","startDate":"2021-02-24","conditions":"Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL), Philadelphia Chromosome-Like ALL (Ph-like ALL)","enrollment":11},{"nctId":"NCT05192889","phase":"PHASE1, PHASE2","title":"Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-08-25","conditions":"Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia","enrollment":35},{"nctId":"NCT03860844","phase":"PHASE2","title":"Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-08-06","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":67},{"nctId":"NCT00476190","phase":"PHASE2","title":"ALL Adult Consortium Trial: Adult ALL Trial","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2007-04","conditions":"Acute Lymphoblastic Leukemia","enrollment":112},{"nctId":"NCT03643276","phase":"PHASE3","title":"Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017","status":"RECRUITING","sponsor":"Martin Schrappe","startDate":"2018-07-15","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":5000},{"nctId":"NCT01228331","phase":"PHASE2, PHASE3","title":"Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2010-10","conditions":"Leukemia","enrollment":745},{"nctId":"NCT00557193","phase":"PHASE3","title":"Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-01-15","conditions":"Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Childhood T Acute Lymphoblastic Leukemia","enrollment":218},{"nctId":"NCT00381680","phase":"PHASE3","title":"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-03","conditions":"B-cell Childhood Acute Lymphoblastic Leukemia, L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia","enrollment":275},{"nctId":"NCT01700946","phase":"PHASE2","title":"Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-04-15","conditions":"Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood B-Lymphoblastic Lymphoma","enrollment":80},{"nctId":"NCT00549848","phase":"PHASE3","title":"Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-10-29","conditions":"Acute Lymphoblastic Leukemia","enrollment":600},{"nctId":"NCT00198991","phase":"PHASE4","title":"German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)","status":"COMPLETED","sponsor":"Goethe University","startDate":"2003-04","conditions":"Adult Acute Lymphocytic Leukemia","enrollment":1883},{"nctId":"NCT03564470","phase":"PHASE2, PHASE3","title":"Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-02-14","conditions":"Leukemia, Leukemia, Acute, Leukemia, Lymphoblastic","enrollment":120},{"nctId":"NCT01451515","phase":"PHASE2","title":"NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2012-05-25","conditions":"Lymphoblastic Lymphoma","enrollment":23},{"nctId":"NCT01117441","phase":"PHASE3","title":"International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"University Hospital Schleswig-Holstein","startDate":"2010-06","conditions":"Leukemia","enrollment":6136},{"nctId":"NCT00137111","phase":"PHASE3","title":"Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2000-07-08","conditions":"Lymphoblastic Leukemia, Acute","enrollment":501},{"nctId":"NCT00720109","phase":"PHASE2, PHASE3","title":"Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-14","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":63},{"nctId":"NCT02518750","phase":"PHASE2","title":"Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-11-23","conditions":"Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's, Leukemia, T-Cell","enrollment":3},{"nctId":"NCT03564704","phase":"PHASE2, PHASE3","title":"Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-02-14","conditions":"Leukemia, Leukemia, Acute, Adult Lymphoblastic Lymphoma","enrollment":80},{"nctId":"NCT03553238","phase":"PHASE2, PHASE3","title":"Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-02-14","conditions":"Leukemia, Acute, Leukemia, T Cell, Leukemia, Lymphoblastic","enrollment":70},{"nctId":"NCT00186875","phase":"PHASE2","title":"Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2003-11","conditions":"Acute Lymphoblastic Leukemia, Lymphoma, Lymphoblastic","enrollment":47},{"nctId":"NCT02660762","phase":"PHASE2","title":"Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-01","conditions":"Leukaemia,Lymphoblastic","enrollment":100},{"nctId":"NCT00096135","phase":"NA","title":"Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2004-11","conditions":"Leukemia","enrollment":168},{"nctId":"NCT00002665","phase":"PHASE2","title":"SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1995-07","conditions":"Leukemia, Neutropenia, Thrombocytopenia","enrollment":50},{"nctId":"NCT00002785","phase":"PHASE2","title":"Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1996-07","conditions":"Leukemia","enrollment":""},{"nctId":"NCT00940524","phase":"PHASE1","title":"Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2009-07","conditions":"Leukemia, Acute Lymphoblastic Leukemia","enrollment":7},{"nctId":"NCT00022737","phase":"PHASE3","title":"Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-10","conditions":"Childhood Acute Lymphoblastic Leukemia in Remission, Recurrent Childhood Acute Lymphoblastic Leukemia","enrollment":220},{"nctId":"NCT01005758","phase":"PHASE2","title":"Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2009-01","conditions":"Leukemia","enrollment":180},{"nctId":"NCT00002816","phase":"PHASE3","title":"Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1996-12","conditions":"Leukemia","enrollment":120},{"nctId":"NCT00187005","phase":"PHASE3","title":"Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"1998-07","conditions":"Acute Lymphoblastic Leukemia","enrollment":53}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HR 3'"],"phase":"phase_3","status":"active","brandName":"Dexamethasone, Cytarabine, Etoposide, Pegylated-asparaginase","genericName":"Dexamethasone, Cytarabine, Etoposide, Pegylated-asparaginase","companyName":"Children's Cancer Group, China","companyId":"children-s-cancer-group-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination regimen uses a corticosteroid, cytotoxic chemotherapy agents, and an amino acid-depleting enzyme to induce apoptosis and inhibit protein synthesis in leukemic cells. Used for Acute lymphoblastic leukemia (ALL) in pediatric patients, Acute myeloid leukemia (AML) in pediatric patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}